Dizal Pharmaceutical Co Valuation Multiples
Dizal Pharmaceutical Co is valued at $4.7B as of November 2026, a 5.8x revenue multiple. In the last 12 months, Dizal Pharmaceutical Co revenue was $697M and Dizal Pharmaceutical Co EBITDA was $462M.
Dizal Pharmaceutical Co Overview
About Dizal Pharmaceutical Co
Dizal Pharmaceutical Co Ltd, formerly Dizal (Jiangsu) Pharmaceutical Co Ltd is engaged in the research and development, production and sales of innovative drugs.
Founded
2017
HQ
Employees
N/A
Website
Financials (LTM)
EV
$4B
Valuation Multiples
Start free trial
Dizal Pharmaceutical Co Financials
Dizal Pharmaceutical Co reported last 12-month revenue of $697M and EBITDA of $462M.
In the same LTM period, Dizal Pharmaceutical Co generated $689M in gross profit, $462M in EBITDA, and $404M in net income.
Dizal Pharmaceutical Co P&L
In the most recent fiscal year, Dizal Pharmaceutical Co reported revenue of $120M and EBITDA of ($100M).
Dizal Pharmaceutical Co is unprofitable as of last fiscal year, with gross margin of 96%, EBITDA margin of (84%), and net margin of (95%).
Financial data powered by Morningstar, Inc.
Dizal Pharmaceutical Co Stock Performance
Dizal Pharmaceutical Co has current market cap of $4.7B, and enterprise value of $4B.
Market Cap Evolution
Dizal Pharmaceutical Co's stock price is $10.07.
Dizal Pharmaceutical Co has an EPS (earnings per share) of $-0.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4.7B | 0.0% | - | - | - | $-0.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDizal Pharmaceutical Co Valuation Multiples
Dizal Pharmaceutical Co trades at 5.8x EV/Revenue multiple, and 8.8x EV/EBITDA.
Dizal Pharmaceutical Co Financial Valuation Multiples
As of November 8, 2026, Dizal Pharmaceutical Co has market cap of $4.7B and EV of $4B.
Dizal Pharmaceutical Co has a P/E ratio of 11.6x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dizal Pharmaceutical Co Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dizal Pharmaceutical Co Margins & Growth Rates
Dizal Pharmaceutical Co grew revenue by 562% but EBITDA decreased by 648% in the last fiscal year.
In the most recent fiscal year, Dizal Pharmaceutical Co reported gross margin of 96%, EBITDA margin of (84%), and net margin of (95%).
Dizal Pharmaceutical Co Margins
Dizal Pharmaceutical Co Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Dizal Pharmaceutical Co Operational KPIs
Dizal Pharmaceutical Co's Rule of 40 is 631% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dizal Pharmaceutical Co's Rule of X is 1474% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Dizal Pharmaceutical Co Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Dizal Pharmaceutical Co competitors and their valuation data. Start Free Trial | ||||||
Dizal Pharmaceutical Co VC Funding History
Before going public, Dizal Pharmaceutical Co raised $100M in total equity funding, across 1 round.
Dizal Pharmaceutical Co Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dizal Pharmaceutical Co
| When was Dizal Pharmaceutical Co founded? | Dizal Pharmaceutical Co was founded in 2017. |
| Where is Dizal Pharmaceutical Co headquartered? | Dizal Pharmaceutical Co is headquartered in China. |
| Is Dizal Pharmaceutical Co publicly listed? | Yes, Dizal Pharmaceutical Co is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Dizal Pharmaceutical Co? | Dizal Pharmaceutical Co trades under 688192 ticker. |
| When did Dizal Pharmaceutical Co go public? | Dizal Pharmaceutical Co went public in 2021. |
| Who are competitors of Dizal Pharmaceutical Co? | Dizal Pharmaceutical Co main competitors include |
| What is the current market cap of Dizal Pharmaceutical Co? | Dizal Pharmaceutical Co's current market cap is $4.7B. |
| What is the current revenue of Dizal Pharmaceutical Co? | Dizal Pharmaceutical Co's last 12 months revenue is $697M. |
| What is the current revenue growth of Dizal Pharmaceutical Co? | Dizal Pharmaceutical Co revenue growth (NTM/LTM) is (45%). |
| What is the current EV/Revenue multiple of Dizal Pharmaceutical Co? | Current revenue multiple of Dizal Pharmaceutical Co is 5.8x. |
| What is the current EBITDA of Dizal Pharmaceutical Co? | Dizal Pharmaceutical Co's last 12 months EBITDA is $462M. |
| What is Dizal Pharmaceutical Co's EBITDA margin? | Dizal Pharmaceutical Co's last 12 months EBITDA margin is 66%. |
| What is the current EV/EBITDA multiple of Dizal Pharmaceutical Co? | Current EBITDA multiple of Dizal Pharmaceutical Co is 8.8x. |
| How many companies Dizal Pharmaceutical Co has acquired to date? | Dizal Pharmaceutical Co hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Dizal Pharmaceutical Co has invested to date? | Dizal Pharmaceutical Co hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including Dizal Pharmaceutical Co
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.